

Cytokine ELISA Kits
Therapeutic Antibody & Cell-Gene Therapy Research
Ultra-Sensitive Detection
Validated for Real Biological Matrices
Consistent Performance, Lot After Lot
Rapid & Robust Workflow
Complete Validation Documentation
Quality Data Interpolation
Ideal for CGT & mAb Programs
Cytokine ELISA Kits
Therapeutic Antibody & Cell-Gene Therapy Research
Ultra-Sensitive Detection
Validated for Real Biological Matrices
Consistent Performance, Lot After Lot
Rapid & Robust Workflow
Complete Validation Documentation
Quality Data Interpolation
Ideal for CGT & mAb Programs
20,000+ ELISA
Specific assays for every scientist
Validated Assays
Quality reagents and a thorough validation protocol
Expert Technical Support
Prompt responses and scientific assistance
Explore ELISA
Our Latest Products
Popular Research Areas
ONCOLOGY
Specific ELISA for oncology markers and related monoclonal / bispecific antibody drugs.
INFLAMMATION
Specific ELISA for inflammation and allergy markers, cytokines and related mAb drugs.
DIABETES / METABOLISM
Specific ELISA for metabolism pathway markers and diabetes biosimilar.
Why Krishgen ELISA?
Why Krishgen ELISA? Because we deliver reliable, accurate, and ready-to-use ELISA kits trusted by researchers worldwide for consistent results.
High Sensitivity & Specificity
Designed for precise detection with reproducible outcomes.
Wide Range of Applications
Wide range of ELISA covering clinical, food, feed, and research needs.
Trusted Quality
Manufactured under stringent quality standards with global customer support.
Featured Citations
PMID: 27568029
DOI: 10.1007/s00210-016-1290-y
In the recent study by Mohd Ashif Khan et al., exploring early manifestations of mild cognitive impairment in B-cell non-Hodgkin’s lymphoma (NHL) patients undergoing CHOP and R-CHOP chemotherapy, interleukin-6 (IL-6) emerged as a crucial biomarker. This study highlights the clinical value of IL-6 monitoring not just for immune response tracking, but as a potential predictive marker for neurotoxicity in cancer therapy.
Patil, S., Gupta, K., Pandit, A. et al. Oral Delivery of Peptide Formulations and Their Cellular Evaluation. Int J Pept Res Ther 27, 2831–2844 (2021). https://doi.org/10.1007/s10989-021-10293-x.
In the study by Patil et al. (2021), titled “Oral Delivery of Peptide Formulations and Their Cellular Evaluation”, the determination of liraglutide levels played a pivotal role in evaluating the effectiveness of novel oral delivery systems.
Food & Feed ELISA
Our food and feed ELISA kits deliver accurate, reliable testing solutions to detect allergens, toxins, and contaminants. We empower the industry with fast, easy-to-use tools that ensure safety, compliance, and quality assurance.
Popular ELISA Used Globally
Upcoming Events
9th Annual Conference of the Society for the Study of Xenobiotics SSX 2026
- 10:00 am
- Bengaluru, India
Meet BioIVT × Krishgen Biosystems at Booth #2
WHX Labs Dubai – World Health Expo 2026 (formerly Medlab Middle East)
- 10:00 am
- Dubai World Trade Centre, UAE
Meet Krishgen Biosystems at WHX Labs Dubai
New Blogs
Featured Citation Summary: Pulmonary Semaglutide PK Research at
- 16 January 2026
The development of alternative, patient-friendly drug delivery routes for peptide-based therapeutics continues to be a major focus in pharmaceutical research.
Honouring India’s Scientific Legends: The Minds Behind Modern
- 26 December 2025
Krishgen BioSystems 2026 Calendar Theme Scientific progress is never sudden - it is cumulative. Every modern method, every assay, every
Integrating ELISA in Bioprocessing: Monitoring Critical Quality Attributes
- 24 April 2025
The development and production of biotherapeutics, including monoclonal antibodies, recombinant proteins, and gene therapy vectors, require rigorous control of process-
Popular Targets for Bispecific Antibody Drugs
- 24 March 2025
Popular Targets for Bispecific Antibody Drugs Bispecific Antibody drugs have gained considerable popularity since the approval of blinatumomab. Currently, six bsAb
Semaglutide: An Overview
- 29 December 2023
Semaglutide: An Overview Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable attention in the past couple of years









